<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>TABLE 1</label>
 <caption>
  <p>Dengue vaccines in clinical trials.</p>
 </caption>
 <table frame="hsides" rules="groups" cellspacing="5" cellpadding="5">
  <thead>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Name</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Vaccine type</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Immunogen</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Developer</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Current status</bold>
    </td>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">DENVax (TAK-003)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Live attenuated chimeric vaccine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Attenuated DENV-2; Substitution with DENV-1,3,4 prM and E genes on DENV-2 backbone;</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Takeda Vaccine Inc.</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Phase III</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">LAV Delta 30 (TV003/TV005)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Live attenuated chimeric vaccine</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Attenuated DENV-1,3 and 4, through deletion in 3â€²UTR, DENV-2 prME on the backbone of attenuated DENV-4</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NIAID/Butantan Institute</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Phase III</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">DENV subunit V180</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Subunit protein</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Ectodomain (N-terminal 80%) of envelope protein, expressed in S2 cell line</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Hawaii Biotech Inc./Merk</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Phase I</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">D1ME100</td>
    <td valign="top" align="left" rowspan="1" colspan="1">DNA</td>
    <td valign="top" align="left" rowspan="1" colspan="1">prM and E genes</td>
    <td valign="top" align="left" rowspan="1" colspan="1">US Naval Research Center</td>
    <td valign="top" align="left" rowspan="1" colspan="1">Phase I</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
